<DOC>
	<DOCNO>NCT00510536</DOCNO>
	<brief_summary>The purpose study evaluate tolerability effectiveness conventional treatment mild moderate arthritic arthralgic symptom subject treat efalizumab psoriasis .</brief_summary>
	<brief_title>Treatment Mild Moderate Joint Pain Patients With Chronic Plaque Psoriasis Receiving Efalizumab</brief_title>
	<detailed_description>The study objective demonstrate mild moderate arthritis arthralgia may control use conventional therapy treat efalizumab , without loss efficacy .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Arthralgia</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>Females become pregnant participate study . Have history plaque psoriasis least 6 month . Receiving receive efalizumab treatment chronic plaque psoriasis . Have mild moderate arthritis arthralgia occur treatment efalizumab untreated mild moderate arthritis arthralgia present time initiate treatment efalizumab . Previous systemic treatment biologics efalizumab , within 3 month . Treatment systemic corticosteroid intraarticular corticosteroid injection , cyclosporine methotrexate within 28 day . Any previous treatment chlorambucil cyclophosphamide . Have active tuberculosis currently receive treatment prophylactic therapy tuberculosis . Have serious disorder ; , congestive heart failure , prior current history blood dyscrasia , central nervous system demyelinate disorder . Has sensitivity , intolerance , history gastrointestinal bleeding associate diclofenac , indomethacin , and/or ibuprofen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Psoriasis , arthritis , arthralgia</keyword>
</DOC>